Table 5.
Toxicity during adjuvant temozolomide chemotherapy.
| Characteristic | Group 1 Adjuvant TMZ only N=21 | Group 2 Concurrent & adjuvant TMZ N=22 | P |
|---|---|---|---|
| Thrombocytopenia | |||
| Grade 1 | 3 (14%) | 3 (14%) | |
| Grade 2 | 0 | 0 | 0.0407 |
| Grade 3 | 2 (10%) | 0 | |
| Grade 4 | 4 (19%) | 0 | |
| Leukopenia | |||
| Grade 1 | 4 (19%) | 1 (5%) | |
| Grade 2 | 0 | 5 (23%) | 0.0685 |
| Grade 3 | 1 (5%) | 0 | |
| Grade 4 | 1 (5%) | 1 (5%) | |
| Anemia | |||
| Grade 1 | 1 (5%) | 0 | |
| Grade 2 | 1 (5%) | 1 (5%) | 0.7379 |
| Grade 3 | 0 | 1 (5%) | |
| Grade 4 | 0 | 2 (9%) | |
| Upper GI toxicity | |||
| Grade 1 | 5 (24%) | 5 (23%) | |
| Grade 2 | 1 (5%) | 3 (14%) | 0.5290 |
| Grade 3 | 2 (10%) | 0 | |
| Grade 4 | 0 | 1 (5%) | |
| Radiation dermatitis | |||
| Grade 1 | 8 (38%) | 4 (18%) | |
| Grade 2 | 1 (5%) | 3 (14%) | 0.2576 |
| Grade 3 | 0 | 0 | |
| Grade 4 | 0 | 0 | |